Identifying potential synergy between pleurotin and bacteriophages towards tackling multi- resistant infections.

多重耐药微生物对医疗保健构成重大挑战。目前抗生素发现的局限性使得寻找新的发现方法和来源以及非抗生素替代品成为必要。担子菌衍生的次级代谢物侧耳素及其同系物可能是前者的支持者，因为这些已被证明对革兰氏阳性菌有效，而噬菌体（B.E.）可能是最终的非抗生素替代品。噬菌体可以以高度特异性（抗性）细菌病原体为目标。噬菌体治疗的一个非常有前途的应用是噬菌体-抗生素组合（PAC）治疗，其中噬菌体和常规抗生素的混合物被用于对抗有问题的细菌菌株。在这个项目中，我们希望研究噬菌体和抗生素联合治疗研究的前景，以了解是否可以实现噬菌体-抗生素协同作用（PAS），这可以抑制细菌生长，增加生物膜清除率并抵消细菌耐药性的出现。沿着这一努力，将探讨担子菌衍生的pleurotin及其同源物作为发现感兴趣的新型次级代谢产物的途径。将分析靶向革兰氏阳性金黄色葡萄球菌感染的pleurotin和噬菌体的组合的检查，以揭示人细胞中的效率和细胞毒性。

Multidrug-resistant organisms pose a major healthcare challenge. The current limitations on antibiotic discovery, have necessitated the search for novel discovery methods and sources as well as non-antibiotic alternatives. The basidiomycete-derived, secondary metabolite pleurotin and its congeners could be a proponent of the former, as these have been shown to be effective against gram-positive bacteria, while bacteriophages (phages) could be the ultimate non-antibiotic alternative. Phages can target with great specificity (resistant) bacterial pathogens. A very promising application of bacteriophage therapy is phage-antibiotic combination (PAC) therapy, where cocktails of phage and conventional antibiotic are employed against problematic bacterial strains. In this project, we wish to examine the landscape of phage and antibiotic combination therapy research, to find out if phage-antibiotic synergy (PAS) can be achieved, which could inhibit bacterial growth, increase biofilm clearance and counteract the emergence of bacterial resistance. Along this effort, the basidiomycete-derived pleurotin and its congeners will be explored as ways to discover novel secondary metabolites of interest. An examination of the combination of pleurotin and bacteriophages targeting the gram-positive Staphylococcus aureus infections will be analysed to reveal efficiency and cytotoxicity in human cells.